Literature DB >> 12174326

Pathways from obesity to hypertension: from the perspective of a vicious triangle.

J-P Montani1, V Antic, Z Yang, Abdul Dulloo.   

Abstract

Obesity and arterial hypertension are important public health problems. Both overweight and hypertension predispose to cardiovascular diseases, such as myocardial infarction, stroke and renal failure. Moreover, overweight clearly predisposes to hypertension, and thus to an increased prevalence of cardiovascular diseases. This in turn favors inactivity and further weight gain, leading to an exacerbation of cardiovascular disorders. Obesity, hypertension and cardiovascular diseases thus contribute to three corners of a vicious triangle. It is within this conceptual framework that this paper reviews the pathogenesis of obesity-related hypertension, which is highly complex. Many factors act together to promote vasoconstriction and sodium retention. Leptin, free fatty acids and insulin, whose levels are increased in obesity, may act synergistically to stimulate sympathetic activity and vasoconstriction. In addition, obesity-induced insulin resistance and endothelial dysfunction may operate as amplifiers of the vasoconstrictor response. Finally, increased renal tubular reabsorption of sodium may also occur, caused by an increased renal sympathetic nerve activity, the direct effect of insulin, hyperactivity of the renin-angiotensin system and possibly by an alteration of intrarenal physical forces. All together, these factors will lead to sustained hypertension. Because the prevalence of obesity was steadily increasing in the last decades, leading to an increased prevalence of hypertension and cardiovascular disorders, obesity and hypertension will most likely become the health challenges of the twenty-first century.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12174326     DOI: 10.1038/sj.ijo.0802125

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  32 in total

Review 1.  The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome.

Authors:  Tina Thethi; Masumi Kamiyama; Hiroyuki Kobori
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

Review 2.  Impact of obesity as an independent risk factor for the development of renal injury: implications from rat models of obesity.

Authors:  Kasi C McPherson; Corbin A Shields; Bibek Poudel; Brianca Fizer; Alyssa Pennington; Ashley Szabo-Johnson; Willie L Thompson; Denise C Cornelius; Jan M Williams
Journal:  Am J Physiol Renal Physiol       Date:  2018-12-12

Review 3.  Bariatric surgery and renal function.

Authors:  Andrew Currie; Andrew Chetwood; Ahmed R Ahmed
Journal:  Obes Surg       Date:  2011-04       Impact factor: 4.129

Review 4.  The impacts of obesity on the cardiovascular and renal systems: cascade of events and therapeutic approaches.

Authors:  Zohreh Soltani; Vaughn Washco; Stephen Morse; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2015-02       Impact factor: 5.369

Review 5.  Obesity: Current and potential pharmacotherapeutics and targets.

Authors:  Vidya Narayanaswami; Linda P Dwoskin
Journal:  Pharmacol Ther       Date:  2016-10-20       Impact factor: 12.310

6.  Leptin-Induced Sympathetic Nerve Activation: Signaling Mechanisms and Cardiovascular Consequences in Obesity.

Authors:  Kamal Rahmouni
Journal:  Curr Hypertens Rev       Date:  2010-05-01

7.  Role of the histone deacetylase inhibitor valproic acid in high-fat diet-induced hypertension via inhibition of HDAC1/angiotensin II axis.

Authors:  J Choi; S Park; T K Kwon; S I Sohn; K M Park; J I Kim
Journal:  Int J Obes (Lond)       Date:  2017-07-19       Impact factor: 5.095

8.  Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders.

Authors:  David J Heal; Jane Gosden; Sharon L Smith
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

9.  Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.

Authors:  Hiroaki Masuzaki; Hiroshi Yamamoto; Christopher J Kenyon; Joel K Elmquist; Nicholas M Morton; Janice M Paterson; Hiroshi Shinyama; Matthew G F Sharp; Stewart Fleming; John J Mullins; Jonathan R Seckl; Jeffrey S Flier
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

10.  Possible Link between Metabolic Syndrome and Chronic Kidney Disease in the Development of Cardiovascular Disease.

Authors:  Kosaku Nitta
Journal:  Cardiol Res Pract       Date:  2010-10-07       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.